

AbbVie expands Biologics Manufacturing Capacity with \$223 M investment at Singapore Site

25 January 2024 | Company results

Located in Singapore's Tuas Biomedical Park, AbbVie's Singapore plant is a state-of-the-art small-molecule and biologics manufacturing facility serving global markets. Operations expected to commence in 2026.



AbbVie expanded its Singapore manufacturing facility on 25th Jan, strengthening its manufacturing capabilities. With a new \$223 million (S\$301 million) investment, A state-of-the-art facility for manufacturing biologics and small molecules, AbbVie's Singapore plant is located in Singapore's Tuas Biomedical Park. Construction on the expansion will begin late 2024, with operations expected to commence in 2026.

AbbVie will add over 100 employment opportunities and biologics manufacturing capacity to its worldwide network. In other words, the new investment will add 24,000 litres of biologics drug-substance capacity to AbbVie's global manufacturing network and support current products as well as emerging immunology and oncology compounds within AbbVie's pipeline.

AbbVie has invested more than \$740 million (S\$1 billion) in acquiring, modernising and expanding its Singapore facility over the past 10 years. When fully operational, the expanded Singapore manufacturing facility – AbbVie's only manufacturing site in Asia – will employ more than 500 people in manufacturing, quality assurance, supply chain, engineering and administration roles.

Dr Azita Saleki-Gerhardt AbbVie Executive Vice President, Chief Operations Officer. Explained that, "This expansion announcement represents one of AbbVie's many investments in its Singapore-based operations and the proud continuation of our decade-long partnership with the Government of Singapore. The expansion of our Singapore site will strengthen our global manufacturing capabilities, support our growing biologics pipeline and help AbbVie continue delivering on our patient commitments now and in the future."

"We are delighted that AbbVie has chosen to expand its biologics capacity in Singapore for current and future innovative medicines. We are grateful for AbbVie's continued trust in the strength of Singapore's biopharmaceutical manufacturing capabilities and talent base. AbbVie's investment will enhance Singapore's leading advanced manufacturing ecosystem and create exciting job opportunities here," said Cindy Koh, Executive Vice President, Singapore Economic Development Board.

AbbVie's Singapore manufacturing plant is a part of AbbVie's Operations team, which consists of 14,000 employees working at more than 30 manufacturing, operations and logistics sites across the United States, Asia, Europe, Puerto Rico and South

